結合
MIP-1α基因轉殖之腫瘤細胞疫苗與樹突細胞疫苗以抑制腫瘤
生長之研究
Study on the Inhibition of Tumor Growth by MIP-1α-transfected
Tumor Cell Vaccine and Dendritic Cell Vaccine
中文摘要
Mouse macrophage inflammatory protein (mMIP) -1α是屬於 C-C chemokines 的一
員，吸引的對象細胞包括巨噬細胞和淋巴球等，進而造成發炎反應；已知MIP-1 α的表現能在腫瘤生長處，協同宿主的抗原呈現細胞 (antigen-presenting cells, APCs) 引發具專一性的抗腫瘤細胞毒殺反應；依此特性製作 mMIP-1α轉殖的腫 瘤細胞疫苗，再結合體外處理的APCs，設計出複合式疫苗，預期對老鼠的腫瘤 細胞生長能夠有加強抑制的效果。利用核酸轉殖 (transfection) 的技術，將一個 含有mMIP-1α基因的載體送入老鼠的腫瘤細胞，CT26 (BALB/c) 及 B16F10 (C57BL/6J) ，並利用酵素聯結免疫吸附分析測試 (ELISA) 篩選出能持續表現 mMIP-1α的單株細胞；自老鼠的股骨、脛骨取出骨髓細胞，加入 mGM-CSF、 mIL-4 等細胞激素刺激其中的單核球分化成為樹突細胞 (dendritic cells, DCs)。我
們的假設為：先以mMIP-1α轉殖的腫瘤細胞疫苗注射老鼠，使其在注射部位產 生發炎反應，隔天再於同一位置注射經體外處理後攜帶有腫瘤抗原的樹突細胞疫 苗，預期接受此種複合性疫苗的老鼠更能有效降低或抑制腫瘤細胞的生長，表示 mMIP-1α不但能在體內增加週邊 DCs 浸潤到疫苗注射部位，其所引起的發炎反 應也可進一步刺激、活化額外注入的DCs，進一步增強抑制腫瘤生長的免疫反應。 我們的實驗結果顯示，不論是BALB/c 或 C57BL/6J 老鼠，在單獨注射 mMIP-1 α轉殖的腫瘤細胞疫苗時，對腫瘤細胞的生長都沒有明顯的抑制效果，但是在注 射樹突細胞疫苗時，抑制腫瘤生長的效果明顯增強，而在結合兩種疫苗後，發現 其效果略勝於單獨注射樹突細胞疫苗；同時我們將兩疫苗注射於同點與不同點的 結果相比較，在BALB/c 老鼠並沒有看出差異，但在 C57BL/6J 老鼠的結果發現 注射於同一點所產生的抑制能力較強，顯示兩種疫苗之間是有互相加成的效果。 結論是，樹突細胞疫苗對腫瘤生長的抑制已經有很好的效果，雖然mMIP-1α轉 殖的腫瘤細胞疫苗沒有如預期的結果，但當兩者結合後，仍達到加成的效果；也 許未來能以樹突細胞疫苗為主，配合不同條件的mMIP-1α或其他趨化激素轉殖 的腫瘤細胞疫苗做研究，期待找出更強的疫苗組合，以達到抑制腫瘤生長的效果。 英文摘要
Mouse macrophage inflammatory protein (mMIP) -1α is a member of the C-C
chemokines. It attracts cells including macrophages, lymphocytes and others, and can induce inflammatory responses. It has been reported that the manifestation of MIP-1α
can coordinate the antigen presenting cells (APCs) of host to induce specific anti-tumor cytotoxicity in the place where tumor grows.
Our hypothesis is that if we injected mMIP-1α-transfected tumor cell vaccine into mice subcutaneously, we can induce inflammation at the site of injection. If we then inject DC which already carries tumor antigens at the same site, the inflammatory environment might further promote the maturation and activation of these injected, antigen-pulsed DC. We expect that mice treated with this kind of complex vaccines can effectively reduce or suppress the growth of tumor cells. Our results indicate that in both BALB/c and C57BL/6J mice, injection of mMIP-1α-transfected tumor cell vaccine alone did not significantly inhibit tumor growth. Injection of DCs vaccine increased the efficiency of inhibition on tumor growth. When we combined these two vaccines, the efficiency was slightly better than injection with DC vaccine alone. We have found that the efficiency of tumor inhibition was better if the two vaccines were injected at the same site in C57BL/6J mice, but not in BALB/c mice. In conclusion, mMIP-1α-transfected tumor cell vaccine alone did not demonstrate the expected efficiency of tumor inhibition, however, DC vaccine appeared to suppress tumor growth in our systems. After we combined the two kinds of vaccine, the efficiency of tumor inhibition was doubled. These results suggest that we can manipulate DC vaccines and tumor cell vaccines, which are modified with mMIP-1α or other chemokines, in the future to find out a more powerful vaccination strategy for effective inhibition of tumor growth.
